Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06465069 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 420
- Enrollment target
- 20
- Study locations
NCT06465069 is a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 420 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT06465069, a Phase 1 study of Non-Small Cell Lung Cancer and Ovarian Cancer, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 420 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Conditions Studied
Interventions
- DRUG LY4052031
Study Locations (20)
Other
- St Vincent's Hospital - Darlinghurst
- Linear Clinical Research - Nedlands
- Institut Gustave Roussy (Igr) - Villejuif
- National Cancer Center Hospital East - Kashiwa, Chiba
- The Cancer Institute Hospital of JFCR - Kōtō City
New York
- Icahn School of Medicine at Mount Sinai - New York
- Columbia University Irving Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- University of Texas MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics (START) - San Antonio
Utah
- University of Utah - Huntsman Cancer Institute - Salt Lake City
- START Mountain Region - West Valley City
California
- City of Hope National Medical Center - Duarte
Colorado
- Sarah Cannon Research Institute at HealthOne - Denver
Florida
- Florida Cancer Specialists and Research Institute - St. Petersburg
Illinois
- University of Chicago Hospital - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2024-07-01 |
| Est. Completion | 2027-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06465069
The ClinicalTrials.gov registry entry for NCT06465069 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (36% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which LY4052031 is the first listed.
NCT06465069 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Other, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT06465069 about?
NCT06465069 is a clinical study titled "A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors". The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-e...
What is the current status of trial NCT06465069?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 420 participants. The study started on 2024-07-01. Estimated completion is 2027-05.
What conditions does trial NCT06465069 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Advanced Solid Tumor, Cervical Cancer.
What interventions are being tested in trial NCT06465069?
The interventions under investigation include: LY4052031 (DRUG).
Who is sponsoring clinical trial NCT06465069?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06465069 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.